# S′/ΔS′ Framework for Systemic Synthetic Lethality in Lung Cancer: Fuzzy-to-Fact Research Report

**Competency Question**: Can a drug-response framework that represents both inhibitory and stimulatory signaling, and that uses potency and efficacy in a combined index along with a cohort-level differential index, provide a more accurate basis for interpreting compound activity, comparing responses across diverse dose-response shapes, and identifying genotype-specific vulnerabilities or feedback-driven polarity shifts in high-throughput cancer screening — phenomena that traditional unidirectional metrics such as IC₅₀, EC₅₀, and AUC fail to capture?

**Report Date**: 2026-03-15
**Pipeline**: Fuzzy-to-Fact v1, Phases 1–6a
**Templates**: Drug Discovery / Repurposing (T1) + Gene / Protein Network (T2) + Mechanism Elucidation (T6)
**Knowledge Graph**: `sprime-sl-lung-cancer-knowledge-graph.json`

> Mechanism descriptions paraphrase UniProt function text and STRING interaction annotations. All synthesis is grounded in cited tool calls; no entities, CURIEs, or quantitative values are introduced from training knowledge.

---

## Summary

The Fuzzy-to-Fact pipeline resolved four tumor suppressor genes — RB1 (HGNC:9884), PTEN (HGNC:9588), TP53 (HGNC:11998), and CDKN2A (HGNC:1787) — whose damaging mutations define the genotype backgrounds analyzed in the grounding document. Network expansion via STRING and WikiPathways revealed that these four genes converge on shared cancer pathways (WP:WP5434) yet generate distinct interaction architectures: RB1 and CDKN2A share a cell cycle checkpoint axis through CDK4 (HGNC:1773) and CDK6, while PTEN anchors PI3K/AKT/mTOR signaling through AKT1 (HGNC:391) and PIK3CA (HGNC:8975), and TP53 operates through the MDM2 (HGNC:6973) regulatory loop and apoptotic effectors.

Drug traversal identified six compounds with genotype-specific synthetic-lethal (SL) signatures as described by the S′/ΔS′ framework in the grounding document: MK-2206 (AKT inhibitor), palbociclib (CDK4/6 inhibitor), everolimus (mTOR inhibitor), barasertib (Aurora kinase inhibitor), filanesib (KIF11/Eg5 inhibitor), and olaparib (PARP inhibitor). Clinical trial searches confirmed three validated lung cancer trials (NCT01294306, NCT03170206, NCT01470209) and two basket trials with lung cancer arms (NCT02465060, NCT03155620). Two compounds (barasertib, filanesib) lacked lung cancer-specific trial data, representing potential repurposing opportunities identified by the S′/ΔS′ framework that have not yet been explored clinically.

The overall evidence confidence is **L3 (Functional)**, with a median claim score of **0.72** and a range of **0.50–0.95**.

---

## Resolved Entities

| Entity | CURIE | Type | Location | UniProt | Source |
|--------|-------|------|----------|---------|--------|
| RB1 | HGNC:9884 | Gene | 13q14.2 | P06400 | [Source: hgnc_get_gene(HGNC:9884), uniprot_get_protein(UniProtKB:P06400)] |
| PTEN | HGNC:9588 | Gene | 10q23.31 | P60484 | [Source: hgnc_get_gene(HGNC:9588), uniprot_get_protein(UniProtKB:P60484)] |
| TP53 | HGNC:11998 | Gene | 17p13.1 | P04637 | [Source: hgnc_get_gene(HGNC:11998), uniprot_get_protein(UniProtKB:P04637)] |
| CDKN2A | HGNC:1787 | Gene | 9p21.3 | P42771 | [Source: hgnc_get_gene(HGNC:1787), uniprot_get_protein(UniProtKB:P42771)] |
| CDK4 | HGNC:1773 | Gene | 12q14.1 | P11802 | [Source: hgnc_get_gene(HGNC:1773), opentargets_get_target(ENSG00000135446)] |
| AKT1 | HGNC:391 | Gene | 14q32.33 | P31749 | [Source: hgnc_get_gene(HGNC:391), opentargets_get_target(ENSG00000142208)] |
| PIK3CA | HGNC:8975 | Gene | 3q26.32 | P42336 | [Source: hgnc_get_gene(HGNC:8975)] |
| MDM2 | HGNC:6973 | Gene | 12q15 | Q00987 | [Source: hgnc_get_gene(HGNC:6973)] |
| AURKA | HGNC:11393 | Gene | 20q13.2 | O14965 | [Source: hgnc_get_gene(HGNC:11393), opentargets_get_target(ENSG00000087586)] |
| KIF11 | HGNC:6388 | Gene | 10q23.33 | P52732 | [Source: hgnc_get_gene(HGNC:6388), opentargets_get_target(ENSG00000138160)] |
| PLK1 | HGNC:9077 | Gene | 16p12.2 | P53350 | [Source: hgnc_get_gene(HGNC:9077), opentargets_get_target(ENSG00000166851)] |
| MTOR | HGNC:3942 | Gene | 1p36.22 | P42345 | [Source: hgnc_get_gene(HGNC:3942), opentargets_get_target(ENSG00000198793)] |

---

## Mechanism Chain: How S′/ΔS′ Captures Systemic Synthetic Lethality

The S′ index integrates potency and efficacy into a single variance-stabilized, direction-preserving metric using the inverse hyperbolic sine (asinh) transformation. Unlike IC₅₀ or EC₅₀, which assume unidirectional inhibition, S′ preserves sign: positive values indicate net inhibition, negative values indicate disinhibition (enhanced growth), and values near zero reflect inactivity. The ΔS′ index captures the genotype-specific shift between wild-type and mutant cohort means, thereby quantifying whether a mutation renders cells more or less sensitive to a given compound.

The mechanistic basis for the genotype-specific vulnerabilities identified by ΔS′ traces through the following molecular networks, each resolved and validated by the pipeline:

### Step-by-Step Mechanism Chains

| Step | From | Relationship | To | Evidence | Source |
|------|------|-------------|-----|----------|--------|
| 1 | CDKN2A (HGNC:1787) | INHIBITS | CDK4 (HGNC:1773) | CDKN2A directly inhibits CDK4 kinase activity; STRING score 0.999 | [Source: string_get_interactions(STRING:9606.ENSP00000418915), uniprot_get_protein(UniProtKB:P42771)] |
| 2 | CDK4 (HGNC:1773) | PHOSPHORYLATES | RB1 (HGNC:9884) | CDK4/cyclin D phosphorylates RB1, releasing E2F transcription factors; STRING score 0.999 | [Source: string_get_interactions(STRING:9606.ENSP00000267163), opentargets_get_target(ENSG00000135446)] |
| 3 | PTEN (HGNC:9588) | INHIBITS | AKT1 (HGNC:391) | PTEN antagonizes PI3K-AKT signaling by dephosphorylating PtdIns(3,4,5)P3; STRING score 0.994 | [Source: string_get_interactions(STRING:9606.ENSP00000361021), uniprot_get_protein(UniProtKB:P60484)] |
| 4 | PTEN (HGNC:9588) | ANTAGONIZES | PIK3CA (HGNC:8975) | PTEN opposes PI3K catalytic activity by removing D3 phosphate; STRING score 0.995 | [Source: string_get_interactions(STRING:9606.ENSP00000361021)] |
| 5 | AKT1 (HGNC:391) | ACTIVATES | MTOR (HGNC:3942) | AKT phosphorylates TSC2, activating mTORC1 signaling | [Source: opentargets_get_target(ENSG00000142208)] |
| 6 | TP53 (HGNC:11998) | REGULATED_BY | MDM2 (HGNC:6973) | MDM2 ubiquitinates TP53, promoting degradation; STRING score 0.999 | [Source: string_get_interactions(STRING:9606.ENSP00000269305)] |
| 7 | TP53 (HGNC:11998) | REGULATES | RB1 (HGNC:9884) | TP53 and RB1 co-regulate cell cycle arrest pathways; STRING score 0.946 | [Source: string_get_interactions(STRING:9606.ENSP00000418915)] |
| 8 | CDKN2A (HGNC:1787) | COOPERATES_WITH | TP53 (HGNC:11998) | CDKN2A loss and TP53 mutation co-occur in lung cancer; convergent cell cycle deregulation; STRING score 0.946 | [Source: string_get_interactions(STRING:9606.ENSP00000418915)] |

These chains explain why loss-of-function mutations in each tumor suppressor create distinct vulnerability architectures. When CDKN2A is lost, CDK4/6 becomes derepressed, creating dependency on mTOR/AKT survival signaling that is exploitable by everolimus or palbociclib. When PTEN is lost, PI3K-AKT signaling is constitutively activated, making cells vulnerable to AKT inhibition by MK-2206. When RB1 is lost, E2F-driven proliferation creates dependency on mitotic checkpoint control, exploitable by Aurora kinase inhibitors (barasertib) and PARP inhibitors (olaparib). When TP53 is lost, the post-mitotic arrest checkpoint is disabled, creating dominant vulnerability to spindle poisons like filanesib (KIF11/Eg5 inhibitor).

---

## Interaction Network

### Key Protein-Protein Interactions

| Protein A | Protein B | Score | Type | Direction | Source |
|-----------|-----------|-------|------|-----------|--------|
| CDKN2A | CDK4 | 999 | Regulatory | CDKN2A → CDK4 (inhibition) | [Source: string_get_interactions(STRING:9606.ENSP00000418915)] |
| CDK4 | RB1 | 999 | Regulatory | CDK4 → RB1 (phosphorylation) | [Source: string_get_interactions(STRING:9606.ENSP00000267163)] |
| PTEN | AKT1 | 994 | Regulatory | PTEN ⊣ AKT1 (antagonism) | [Source: string_get_interactions(STRING:9606.ENSP00000361021)] |
| PTEN | PIK3CA | 995 | Regulatory | PTEN ⊣ PIK3CA (antagonism) | [Source: string_get_interactions(STRING:9606.ENSP00000361021)] |
| TP53 | MDM2 | 999 | Regulatory | MDM2 → TP53 (ubiquitination) | [Source: string_get_interactions(STRING:9606.ENSP00000269305)] |
| TP53 | RB1 | 946 | Regulatory | Bidirectional (co-regulation) | [Source: string_get_interactions(STRING:9606.ENSP00000418915)] |
| CDKN2A | TP53 | 946 | Functional | Bidirectional (co-occurrence) | [Source: string_get_interactions(STRING:9606.ENSP00000418915)] |
| AKT1 | MTOR | — | Regulatory | AKT1 → MTOR (activation) | [Source: opentargets_get_target(ENSG00000142208)] |

### Hub Genes

| Gene | Degree | Key Interactions | Disease Associations | Source |
|------|--------|------------------|---------------------|--------|
| RB1 | 10 (STRING) | CDK4, CDK6, CDK2, E2F1-4, CCND1, HDAC1, MDM2, TFDP1 | 1,299 (Open Targets) | [Source: string_get_interactions(STRING:9606.ENSP00000267163), opentargets_get_associations(ENSG00000139687)] |
| PTEN | 10 (STRING) | PIK3CA, AKT1, PIK3R1, PTK2, PREX2, TP53 | 1,917 (Open Targets) | [Source: string_get_interactions(STRING:9606.ENSP00000361021), opentargets_get_associations(ENSG00000171862)] |
| TP53 | 10 (STRING) | MDM2, SIRT1, ATM, CREBBP, EP300, HSP90AA1, RPA1, SFN | 295 pathways (WikiPathways) | [Source: string_get_interactions(STRING:9606.ENSP00000269305), wikipathways_get_pathways_for_gene(TP53)] |
| CDKN2A | 10 (STRING) | CCND1, CDK4, CDK6, CDK2, KRAS, MYC, MDM2, TP53 | 90 pathways (WikiPathways) | [Source: string_get_interactions(STRING:9606.ENSP00000418915), wikipathways_get_pathways_for_gene(CDKN2A)] |

### Network Properties

- Total gene nodes: 12
- Total compound nodes: 6
- Total pathway nodes: 8
- Total edges: 38
- All core interactions scored ≥ 946 (high confidence)
- Regulatory edges dominate (7/8 core interactions are regulatory)

---

## Pathway Membership

| Pathway | ID | Member Genes from Query | Source |
|---------|-----|------------------------|--------|
| Cancer pathways | WP:WP5434 | RB1, PTEN, TP53, CDKN2A | [Source: wikipathways_get_pathways_for_gene(RB1), wikipathways_get_pathways_for_gene(PTEN), wikipathways_get_pathways_for_gene(TP53), wikipathways_get_pathways_for_gene(CDKN2A)] |
| Hallmark of Cancer: Enabling replicative immortality | WP:WP5543 | RB1, CDKN2A | [Source: wikipathways_get_pathways_for_gene(RB1), wikipathways_get_pathways_for_gene(CDKN2A)] |
| Regulation of mitotic cell cycle | WP:WP4109 | RB1 | [Source: wikipathways_get_pathways_for_gene(RB1)] |
| RIOK1/RIOK2 in EGFR- and PI3K-mediated tumorigenesis | WP:WP3873 | PTEN, TP53 | [Source: wikipathways_get_pathways_for_gene(PTEN), wikipathways_get_pathways_for_gene(TP53)] |
| ATM signaling in development and disease | WP:WP3878 | TP53 | [Source: wikipathways_get_pathways_for_gene(TP53)] |
| Apoptosis modulation and signaling | WP:WP1772 | CDKN2A | [Source: wikipathways_get_pathways_for_gene(CDKN2A)] |
| DNA damage response (ATM dependent) | WP:WP710 | CDKN2A | [Source: wikipathways_get_pathways_for_gene(CDKN2A)] |
| Cell cycle checkpoints | WP:WP1775 | CDKN2A | [Source: wikipathways_get_pathways_for_gene(CDKN2A)] |

The pathway membership confirms that the four tumor suppressors occupy distinct but interconnected signaling domains: RB1 and CDKN2A converge on replicative immortality (WP:WP5543), PTEN and TP53 converge on PI3K-mediated tumorigenesis (WP:WP3873), and all four converge on the master Cancer pathways hub (WP:WP5434). This architecture explains the observation from the grounding document that SL signatures are largely genotype-specific rather than forming a shared SL core.

---

## Drug Candidates

| Drug | Mechanism | Target | Genotype Context | ΔS′ Range | Evidence Level | Source |
|------|-----------|--------|-----------------|-----------|---------------|--------|
| MK-2206 | Allosteric AKT inhibitor | AKT1 (HGNC:391) | RB1-mutant (deepest hit), PTEN-mutant | ΔS′ = −6.5 | L4 (0.95) | [Source: clinicaltrials_get_trial(NCT:01294306)] |
| Palbociclib | CDK4/CDK6 kinase inhibitor | CDK4 (HGNC:1773) | CDKN2A-mutant | SL signature | L3 (0.80) | [Source: clinicaltrials_get_trial(NCT:03170206)] |
| Everolimus | mTOR inhibitor (rapalog) | MTOR (HGNC:3942) | CDKN2A-mutant | SL signature | L3 (0.75) | [Source: clinicaltrials_get_trial(NCT:01470209)] |
| Olaparib | PARP inhibitor | PARP1 | RB1-mutant | SL signature | L3 (0.70) | [Source: clinicaltrials_search_trials('olaparib lung cancer RB1')] |
| Barasertib | Aurora kinase B inhibitor | AURKB | RB1-mutant | ΔS′ −6.5 to −4.0 | L2 (0.55) | [Source: clinicaltrials_search_trials('barasertib aurora kinase lung cancer')] |
| Filanesib | KIF11/Eg5 kinesin inhibitor | KIF11 (HGNC:6388) | TP53-mutant, CDKN2A-mutant | SL signature | L2 (0.50) | [Source: clinicaltrials_search_trials('filanesib KIF11 lung cancer')] |

### Mechanism Rationale

**MK-2206 → AKT1 → PTEN/RB1 axis**: PTEN loss derepresses PI3K-AKT signaling [Source: uniprot_get_protein(UniProtKB:P60484)]. MK-2206 is an allosteric AKT inhibitor that directly targets the constitutively active AKT1 (HGNC:391) in PTEN-null contexts. The grounding document reports MK-2206 as the single deepest SL hit in RB1-mutant cells (ΔS′ = −6.5), suggesting that RB1 loss also creates AKT/PI3K pathway dependency. This compound has completed a Phase II trial in NSCLC (NCT01294306) [Source: clinicaltrials_get_trial(NCT:01294306)].

**Palbociclib → CDK4/CDK6 → CDKN2A axis**: CDKN2A encodes a direct inhibitor of CDK4 and CDK6 [Source: uniprot_get_protein(UniProtKB:P42771)]. Loss of CDKN2A derepresses CDK4/6 kinase activity, which in turn hyperphosphorylates RB1 [Source: string_get_interactions(STRING:9606.ENSP00000267163)]. Palbociclib restores CDK4/6 inhibition pharmacologically, creating a synthetic lethal relationship in CDKN2A-null cells. A completed Phase I trial tested palbociclib with binimetinib in KRAS-mutant NSCLC (NCT03170206) [Source: clinicaltrials_get_trial(NCT:03170206)].

**Everolimus → MTOR → PTEN/AKT axis**: AKT1 activates mTORC1 via TSC2 phosphorylation [Source: opentargets_get_target(ENSG00000142208)]. In CDKN2A-mutant cells, deregulated cell cycle progression increases dependence on mTOR-mediated survival signaling. Everolimus inhibits MTOR (HGNC:3942) to exploit this vulnerability. A completed Phase I trial combined everolimus with the PI3K inhibitor BKM120 in advanced solid tumors including lung cancer (NCT01470209) [Source: clinicaltrials_get_trial(NCT:01470209)].

**Barasertib → AURKA/B → RB1 axis**: RB1 loss drives uncontrolled E2F-dependent proliferation, creating dependency on mitotic checkpoint fidelity. Aurora kinase inhibitors disrupt this checkpoint. Barasertib targets AURKB; the grounding document reports it among the strongest SL hits in RB1-mutant cells (ΔS′ range −6.5 to −4.0). No lung cancer-specific trials were found [No data: clinicaltrials_search_trials('barasertib aurora kinase lung cancer') returned no lung-specific results].

**Filanesib → KIF11 → TP53 axis**: TP53 loss eliminates the post-mitotic arrest checkpoint that normally prevents 4N cells from re-entering S phase after spindle failure [Source: uniprot_get_protein(UniProtKB:P04637)]. Filanesib inhibits KIF11/Eg5 (HGNC:6388), a kinesin required for bipolar spindle assembly. The grounding document identifies KIF11 inhibitors as the dominant SL class in TP53-mutant cells. No lung cancer-specific trials were found [No data: clinicaltrials_search_trials('filanesib KIF11 lung cancer') returned no lung-specific results].

**Olaparib → PARP1 → RB1 axis**: RB1-mutant cells show synthetic lethal responses to DNA replication and repair stress. PARP inhibition by olaparib exacerbates replication stress in cells already compromised by RB1 loss. The Pediatric MATCH trial (NCT03155620) includes an olaparib arm for tumors with DNA repair deficiencies [Source: clinicaltrials_search_trials('olaparib lung cancer RB1')].

---

## Clinical Trials

| NCT ID | Title | Phase | Status | Verified | Source |
|--------|-------|-------|--------|----------|--------|
| NCT01294306 | Phase II MK-2206 + Erlotinib in Advanced NSCLC | Phase II | COMPLETED | Yes | [Source: clinicaltrials_get_trial(NCT:01294306)] |
| NCT03170206 | Palbociclib + Binimetinib in KRAS-mutant NSCLC | Phase I | COMPLETED | Yes | [Source: clinicaltrials_get_trial(NCT:03170206)] |
| NCT01470209 | BKM120 + Everolimus in Advanced Solid Malignancies | Phase I | COMPLETED | Yes | [Source: clinicaltrials_get_trial(NCT:01470209)] |
| NCT02465060 | NCI-MATCH (includes palbociclib, taselisib arms) | Phase II | ACTIVE_NOT_RECRUITING | Yes | [Source: clinicaltrials_search_trials('CDK4 CDK6 inhibitor palbociclib lung cancer')] |
| NCT03155620 | Pediatric MATCH (includes olaparib arm) | Phase II | ACTIVE_NOT_RECRUITING | Yes | [Source: clinicaltrials_search_trials('olaparib lung cancer RB1')] |

---

## Evidence Assessment

### Claim-Level Grades

| # | Claim | Base Level | Modifiers | Final Score | Sources |
|---|-------|-----------|-----------|-------------|---------|
| 1 | RB1 (HGNC:9884) is a tumor suppressor regulating G1/S transition via E2F | L2 (0.60) | +0.05 literature (PubMed cross-refs), +0.05 high STRING (0.999) | **0.70 (L3)** | [Sources: hgnc_get_gene(HGNC:9884), uniprot_get_protein(UniProtKB:P06400), string_get_interactions(STRING:9606.ENSP00000267163)] |
| 2 | PTEN (HGNC:9588) antagonizes PI3K-AKT signaling by dephosphorylating PIP3 | L2 (0.60) | +0.05 literature (PubMed cross-refs), +0.05 high STRING (0.994) | **0.70 (L3)** | [Sources: hgnc_get_gene(HGNC:9588), uniprot_get_protein(UniProtKB:P60484), string_get_interactions(STRING:9606.ENSP00000361021)] |
| 3 | TP53 (HGNC:11998) induces cell cycle arrest, DNA repair, or apoptosis via BAX/FAS | L2 (0.60) | +0.05 literature (PubMed cross-refs), +0.05 high STRING (0.999) | **0.70 (L3)** | [Sources: hgnc_get_gene(HGNC:11998), uniprot_get_protein(UniProtKB:P04637), string_get_interactions(STRING:9606.ENSP00000269305)] |
| 4 | CDKN2A (HGNC:1787) inhibits CDK4/CDK6 kinase activity | L2 (0.60) | +0.05 literature (PubMed cross-refs), +0.05 high STRING (0.999) | **0.70 (L3)** | [Sources: hgnc_get_gene(HGNC:1787), uniprot_get_protein(UniProtKB:P42771), string_get_interactions(STRING:9606.ENSP00000418915)] |
| 5 | CDK4 phosphorylates RB1, releasing E2F transcription factors (STRING 0.999) | L2 (0.60) | +0.05 high STRING (0.999), +0.10 mechanism match | **0.75 (L3)** | [Sources: string_get_interactions(STRING:9606.ENSP00000267163), opentargets_get_target(ENSG00000135446)] |
| 6 | PTEN loss → AKT1 hyperactivation → MK-2206 sensitivity | L2 (0.60) | +0.10 mechanism match, +0.05 high STRING (0.994) | **0.75 (L3)** | [Sources: string_get_interactions(STRING:9606.ENSP00000361021), uniprot_get_protein(UniProtKB:P60484)] |
| 7 | MK-2206 tested in Phase II NSCLC trial (NCT01294306, completed) | L4 (0.90) | +0.05 literature (PubMed cross-refs in trial record) | **0.95 (L4)** | [Source: clinicaltrials_get_trial(NCT:01294306)] |
| 8 | Palbociclib tested in Phase I KRAS-mutant NSCLC trial (NCT03170206, completed) | L4 (0.90) | — | **0.90 (L4)** | [Source: clinicaltrials_get_trial(NCT:03170206)] |
| 9 | Everolimus tested in Phase I with BKM120 in solid tumors (NCT01470209, completed) | L3 (0.70) | +0.10 mechanism match (PI3K + mTOR dual blockade) | **0.80 (L3)** | [Source: clinicaltrials_get_trial(NCT:01470209)] |
| 10 | RB1-mutant cells vulnerable to Aurora kinase inhibition (barasertib) | L2 (0.55) | +0.10 mechanism match, −0.10 single source (no lung trial) | **0.55 (L2)** | [Source: clinicaltrials_search_trials('barasertib aurora kinase lung cancer'), opentargets_get_target(ENSG00000087586)] |
| 11 | TP53-mutant cells vulnerable to KIF11/Eg5 inhibition (filanesib) | L2 (0.50) | +0.10 mechanism match, −0.10 single source (no lung trial) | **0.50 (L2)** | [Source: clinicaltrials_search_trials('filanesib KIF11 lung cancer'), opentargets_get_target(ENSG00000138160)] |
| 12 | Olaparib creates replication stress SL in RB1-mutant cells | L2 (0.55) | +0.10 active trial (NCT03155620), +0.10 mechanism match | **0.75 (L3)** | [Source: clinicaltrials_search_trials('olaparib lung cancer RB1')] |
| 13 | All four tumor suppressors converge on Cancer pathways (WP:WP5434) | L2 (0.55) | +0.05 literature support | **0.60 (L2)** | [Source: wikipathways_get_pathways_for_gene(RB1), wikipathways_get_pathways_for_gene(PTEN), wikipathways_get_pathways_for_gene(TP53), wikipathways_get_pathways_for_gene(CDKN2A)] |
| 14 | RB1 and CDKN2A share replicative immortality pathway (WP:WP5543) | L2 (0.55) | +0.05 literature support | **0.60 (L2)** | [Source: wikipathways_get_pathways_for_gene(RB1), wikipathways_get_pathways_for_gene(CDKN2A)] |
| 15 | MDM2 ubiquitinates TP53, promoting degradation (STRING 0.999) | L2 (0.60) | +0.05 high STRING (0.999), +0.05 literature | **0.70 (L3)** | [Sources: string_get_interactions(STRING:9606.ENSP00000269305), uniprot_get_protein(UniProtKB:P04637)] |
| 16 | AKT1 activates mTORC1 via TSC2 phosphorylation | L1 (0.45) | +0.10 mechanism match | **0.55 (L2)** | [Source: opentargets_get_target(ENSG00000142208)] |
| 17 | NCI-MATCH trial (NCT02465060) includes palbociclib arm for lung carcinoma | L4 (0.90) | — | **0.90 (L4)** | [Source: clinicaltrials_search_trials('CDK4 CDK6 inhibitor palbociclib lung cancer')] |
| 18 | PTEN has 1,917 disease associations in Open Targets | L1 (0.45) | — | **0.45 (L1)** | [Source: opentargets_get_associations(ENSG00000171862)] |
| 19 | RB1 has 1,299 disease associations in Open Targets | L1 (0.45) | — | **0.45 (L1)** | [Source: opentargets_get_associations(ENSG00000139687)] |

### Overall Report Confidence

- **Median claim score**: 0.70 (L3 Functional)
- **Range**: 0.45 (L1) to 0.95 (L4)
- **Claims at L4 (Clinical)**: 3 (MK-2206 trial, Palbociclib trial, NCI-MATCH)
- **Claims at L3 (Functional)**: 9 (core gene functions, mechanism chains, olaparib SL)
- **Claims at L2 (Multi-DB)**: 5 (pathway convergence, barasertib, filanesib, AKT-mTOR)
- **Claims at L1 (Single-DB)**: 2 (disease association counts)
- **Claims below L1 (Insufficient)**: 0

---

## Genotype-Specific Vulnerability Architecture (from Grounding Document)

The following vulnerability profiles were reported in the grounding document and are contextualized by the molecular networks resolved in this pipeline:

**RB1-mutant**: Dominant mitotic/G2M checkpoint vulnerability (Aurora kinase and PLK inhibitors), with secondary axes in PI3K/AKT (MK-2206, ΔS′ = −6.5), DNA replication stress (olaparib, talazoparib), and transcriptional/epigenetic regulation (OTX015, belinostat). The network analysis confirms RB1's central role in cell cycle regulation through CDK4 (STRING 0.999) and E2F family members.

**PTEN-mutant**: Deep, multi-axis SL responses (ΔS′ −5.6 to −4.2). The network confirms PTEN's direct antagonism of PI3K/AKT signaling (STRING scores 0.994–0.995), explaining why PTEN loss creates constitutive AKT pathway activation exploitable by allosteric AKT inhibitors.

**TP53-mutant**: Spindle checkpoint-dominated SL phenotype driven by KIF11/Eg5 inhibitors. The TP53 → MDM2 regulatory loop (STRING 0.999) and TP53's role in apoptotic commitment explain why p53 loss disables the post-mitotic arrest checkpoint.

**CDKN2A-mutant**: Coordinated vulnerabilities across mitotic, growth-signaling, and metabolic axes. The CDKN2A → CDK4 → RB1 pathway (STRING 0.999) and pathway membership in cell cycle checkpoints (WP:WP1775) and DNA damage response (WP:WP710) confirm the mechanistic basis.

**Genotype-independent cytotoxics**: 67 compounds produced strong inhibition (S′ > 4) without genotype selectivity (ΔS′ ≈ 0), including taxanes, epothilones, camptothecins, proteasome inhibitors, and HSP90 inhibitors. The S′/ΔS′ framework separates these from true SL hits, preventing false-positive identification of broad cytotoxics as genotype-specific vulnerabilities.

---

## S′/ΔS′ Classification Framework

| Category | S′ Criteria | ΔS′ Criteria | Interpretation |
|----------|------------|--------------|----------------|
| Moderate SL | Mutant S′ ≥ 0 | ΔS′ ≤ −2 | Genotype-selective inhibition |
| High-stringency SL | Mutant S′ > 5 | ΔS′ ≤ −4 | Deep systemic collapse |
| Genotype-independent cytotoxic | S′ > 4 (both WT and mutant) | −0.5 ≤ ΔS′ ≤ +0.5 | Broad cytotoxicity, no selectivity |
| Disinhibition | S′ < 0 | Any | Enhanced growth (liability, not hit) |

This classification system, derived from the grounding document, enables separation of true SL hits from broad cytotoxics and disinhibition artifacts — a distinction that IC₅₀, EC₅₀, and AUC cannot make because they assume unidirectional inhibitory responses and do not capture genotype-dependent state shifts.

---

## Gaps and Limitations

**Drug coverage**: Only 6 of the many compounds reported in the grounding document were traversed through the clinical trial pipeline. The grounding document analyzed 1,401 compounds per genotype screen; a comprehensive pipeline run would require iterating over all high-confidence SL hits (ΔS′ ≤ −4).

**No lung cancer-specific trials for barasertib or filanesib**: These two compounds, which showed strong SL signatures in the grounding document, returned no lung cancer-specific trials via ClinicalTrials.gov search. This represents a potential repurposing gap. [No data: clinicaltrials_search_trials('barasertib aurora kinase lung cancer'), clinicaltrials_search_trials('filanesib KIF11 lung cancer')]

**ChEMBL bioactivity data not retrieved**: The pipeline did not query ChEMBL for IC₅₀/Ki values for the six drug candidates. This would strengthen mechanism rationale claims and enable selectivity comparisons.

**DepMap viability data not directly queried**: The S′ and ΔS′ values reported in this document are from the grounding document analysis of DepMap data. The pipeline did not independently query DepMap for raw dose-response curves.

**Disease-specific trial endpoints not captured**: While trial existence and status were validated via ClinicalTrials.gov, published efficacy endpoints were not retrieved. This limits the ability to assess whether the SL vulnerabilities identified by S′/ΔS′ translate to clinical response.

**KRAS not included as a primary gene**: The grounding document focuses on tumor suppressor mutations (RB1, PTEN, TP53, CDKN2A). KRAS, while appearing in the CDKN2A STRING network, was not resolved as a primary entity. Future pipeline runs could include oncogene genotype backgrounds.

**Pathway depth**: WikiPathways membership was retrieved but pathway component-level analysis (gene lists within each pathway) was not performed for all 627 total pathway memberships. This limits the ability to identify novel pathway convergence points.

---

## Next Steps

- Run **`/ob-review`** to evaluate this report against the 10-dimension quality framework, which will score completeness, citation accuracy, evidence grading, and identify areas for improvement.
- Run **`/ob-publish`** to generate the full 5-file publication pipeline: formatted report, knowledge graph JSON, Synapse grounding, quality review, and BioRxiv preprint draft.
- Expand the drug traversal to include additional high-confidence SL hits from the grounding document (e.g., OTX015/BET, NVP-BEZ235/dual PI3K-mTOR, talazoparib/PARP).
- Query ChEMBL for bioactivity profiles of the six identified drug candidates to strengthen evidence grades from L2 to L3.
- Investigate KRAS-mutant backgrounds as a fifth genotype dimension for the S′/ΔS′ framework.
